Cardiol Therapeutics: B. Riley Sees 450% Upside as Phase 3 MAVERIC Trial Nears Completion

B. Riley initiates Cardiol Therapeutics at Buy with an $11 target, citing a de-risked Phase 3 MAVERIC trial and strong cash runway.